CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies

SIMPLE SUMMARY: Immunotherapies offer broad potential to treat many diseases, including cancer. Macrophages are highly abundant immune cells, but are generally inhibited from eliminating tumor cells by ‘self’ signaling. Blocking this macrophage signaling checkpoint with antibodies has gone through c...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrechak, Jason C., Dooling, Lawrence J., Tobin, Michael P., Zhang, William, Hayes, Brandon H., Lee, Justine Y., Jin, Xiaoling, Irianto, Jerome, Discher, Dennis E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026896/
https://www.ncbi.nlm.nih.gov/pubmed/35454837
http://dx.doi.org/10.3390/cancers14081930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026896/
https://www.ncbi.nlm.nih.gov/pubmed/35454837
http://dx.doi.org/10.3390/cancers14081930

Ejemplares similares